Headline–confidence gap
Headline confirmed
Management confidence reinforces the reported beat.
AMGN · Q3 2026
AMGEN INC
31EarnIQ signal
↗
Confidence rising
Moderate quarter-over-quarter shiftAmgen delivered robust revenue growth and strong volume expansion across key growth drivers despite biosimilar headwinds.
- ✓Guidance was none, with low specificity.
- ✓Management tone registered as confident (85/100).
- ✓EarnIQ detected 0 potential management deflections.
EPS: reported vs expected+9.8%$6.29 vs $5.73
Revenue: reported vs expected+4.6%$10.1B vs $9.6B
Guidance specificityLowChange not comparable
Market expectations supplied by Finnhub · Reported vs consensus estimate
Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales.
Premium intelligence
The evidence behind the signal
Management language
Why confidence moved
“Our results demonstrate strong performance across our business.”
“Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales.”
“As we expand the potential of our existing medicines through new indications and advance the next wave of pipeline molecules through Phase 3, we remain confident in our ability to deliver growth well into the next decade”
Guidance specificity
30/100
Low specificity
No explicit forward-looking numeric guidance ranges were provided in the excerpted release text.
Pressure point
Prolia and XGEVA sales decreased
0 potential deflections detected in management communication.
Narrative break
What changed
No material narrative break was detected this quarter.
Q&A evidence
Management responses
No material Q&A deflections were detected.
Key positives
- Total revenues increased 10% to $10.1 billion, with product sales growing 9% driven by volume growth.
- Six key growth drivers grew 26% year-over-year, generating nearly 70% of second-quarter product sales.
- Free cash flow reached $3.5 billion in the second quarter of 2026 compared to $1.9 billion in the second quarter of 2025.
Key risks
- Prolia and XGEVA sales decreased 32% and 34% respectively, driven by lower volume and net selling price due to biosimilar launches.
- Enbrel sales decreased 4% primarily driven by 22% lower net selling price resulting from U.S. Medicare Part D price setting under the Inflation Reduction Act and increased 340B Program mix.
- Total operating expenses on a non-GAAP basis increased 11% year-over-year, driven by higher profit share expense, manufacturing costs, and R&D spend.
Topic velocity
Language versus prior quarter
M&ANew
CostNew
ChinaNew
MarginNew
RecordNew
iPhoneNew
Signal composition
What drove the EarnIQ score
Tone+20
Eps Beat+0
Guidance+3
New Signal+0
Miss Penalty+0
Qoq Improvement+8
Deflection Penalty+0